H. Naman

Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

François‐Clément Bidard, William Jacot, Nicolas Kiavué et al. · JAMA Oncology · 2020 · 178 citations · Full text

Medicine, Oncology, Chemotherapy +16

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study

Joseph Gligorov, Xavier Pivot, William Jacot et al. · The Oncologist · 2015 · 45 citations · Full text

Medicine, Endocrinology, Oncology +17

Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

F-C Bidard, William Jacot, Sylvain Dureau et al. · Cancer Research · 2019 · 32 citations

Medicine, Oncology, Breast Oncology +16

High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma

Nicolas Martin, Delphine Borchiellini, Diane Coso et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2015 · 22 citations

Medicine, Geriatric Medicine, Oncology +15